KRAS Inhibition in Non-Small Cell Lung Cancer with Central Nervous System Involvement: Current Evidence and Future Directions

Even with recent progress in treatment, brain metastases continue to pose a significant challenge in managing KRAS-mutant NSCLC. Among currently available agents, adagrasib has shown encouraging intracranial activity and CNS penetration, and rational combination strategies are being explored to overcome resistance. Ongoing research should prioritize CNS-specific endpoints and integrated treatment approaches tailored to patients with brain involvement.